Subscribe
shutterstock_1426719905_piotr_swat
Piotr Swat / Shutterstock.com
25 August 2020AmericasSarah Morgan

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

A district judge has given India-based  Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against  Indivior.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA approves Dr Reddy’s Vascepa generic
13 August 2020   Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.
Big Pharma
Indivior appeal fails to stop generic opioid addiction challenge
15 July 2019   The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Americas
FDA approves Dr Reddy’s Vascepa generic
13 August 2020   Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.
Big Pharma
Indivior appeal fails to stop generic opioid addiction challenge
15 July 2019   The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.

More on this story

Americas
FDA approves Dr Reddy’s Vascepa generic
13 August 2020   Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.
Big Pharma
Indivior appeal fails to stop generic opioid addiction challenge
15 July 2019   The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits